Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer, a Phase II Efficacy Study

NCT06180733 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT06180733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06180733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer, a Phase II Efficacy Study
Lead sponsor
University Medical Center Groningen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 1, 2023
Completion date
January 31, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer